In a report issued on May 12, Andrew Berens from SVB Securities maintained a Buy rating on Theseus Pharmaceuticals (THRX – Research Report), with a price target of $18.00. The company's shares closed last Friday at $7.59, close to its 52-week low of $7.00. According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.7% and a 35.0% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theseus Pharmaceuticals with a $18.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-theseus-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Theseus Pharmaceuticals Charts.
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Theseus Pharmaceuticals Charts.